Clinical Trials Sponsored by Mabwell (Shanghai) Bioscience Co., Ltd.

Total 1176 results

Shanghai Junshi Bioscience Co., Ltd.

Unknown

Safety and Efficacy of Recombinant Humanized Anti-PD-1 mAb for Patients With Locally Advanced or Metastatic Melanoma

Metastatic Melanoma | Advanced Melanoma

China
Shanghai Junshi Bioscience Co., Ltd.

Unknown

Safety, Tolerability and Pharmacokinetics of a Recombinant Humanized mAb Specific to B-and T-Lymphocyte Attenuator (BTLA) for Injection in Subjects With Advanced Malignancies

Advanced Solid Tumor

China
Shanghai Junshi Bioscience Co., Ltd.

Unknown

Phase I Study of Comparing Single Dose JS005 (Recombinant Humanized Monoclonal Antibody Against IL-17A) With Placebo in Tolerability, Safety, Immunogenicity and Pharmacokinetic in Healthy Volunteers

Tolerability, Safety, Immunogenicity and Pharmacokinetic of JS005

China
Shanghai Junshi Bioscience Co., Ltd.
Iqvia Pty Ltd; TopAlliance Biosciences, Inc.

Active, not recruiting

Safety, Tolerability and Pharmacokinetics of an Anti-PD-1 Monoclonal Antibody in Subjects With Advanced Malignancies

Advanced Malignancies

United States
Shanghai Vinnerna Biosciences Co., Ltd.

Withdrawn

Evaluate the Pharmacokinetics, Safety and Tolerability of JT001 Tablets

Healthy Subjects

Australia
Shanghai Vinnerna Biosciences Co., Ltd.

Recruiting

A Real-World Study of JT001 for COVID-19

COVID-19

China
Coherus Biosciences, Inc.
Shanghai Junshi Bioscience Co., Ltd.; Medpace, Inc.

Active, not recruiting

Study to Evaluate Safety and PK of CHS-006 in Combination With Toripalimab in Patients With Advanced Solid Tumors

Hepatocellular Carcinoma | Non-Small Cell Lung Cancer | Advanced Solid Tumor

United States
Shanghai Vinnerna Biosciences Co., Ltd.

Recruiting

A Real-world Retrospective Study of Disease Outcomes in Non-severe COVID-19 Patient

COVID-19 Patient

China
Shanghai Vinnerna Biosciences Co., Ltd.

Active, not recruiting

Effect of Pharmacokinetics in Healthy Chinese Subjects

The Effects of Clarithromycin or Cyclosporine on Pharmacokinetics of Deuterium Hydrobromide Ramidvir Tablets in Healthy Chinese Subjects

China
Shanghai Chest Hospital
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

The Effect of Toripalimab Plus Radiotherapy in Patients With Operable Stage II-IIIA (N+) Non Small Cell Lung Cancer

NSCLC

China
Elpiscience Biopharma, Ltd.
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

A Study of ES102 (OX40 Agonist) in Combination With JS001 in Patients With Advanced Solid Tumors

Neoplasms | Solid Tumor | Malignant Tumor

China
Shanghai Junshi Bioscience Co., Ltd.
Sponsor GmbH

Recruiting

A Clinical Study of JS005 in Patients With Ankylosing Spondylitis

Ankylosing Spondylitis

China
Shanghai Junshi Bioscience Co., Ltd.
Sponsor GmbH

Not yet recruiting

A Phase Ib/II Study Of JS015 Combination Therapy in Advanced Solid Tumors

Advanced Solid Tumor

China
Shanghai Junshi Bioscience Co., Ltd.
Sponsor GmbH

Not yet recruiting

The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of JS207 in Patients With Advanced Malignant Tumor

Advanced Malignant Tumor

China
Shanghai Junshi Bioscience Co., Ltd.
Sponsor GmbH

Recruiting

A Phase I Study Of JS015 in Patients With Advanced Solid Tumors

Advanced Solid Cancer

China
Shanghai Junshi Bioscience Co., Ltd.
Sponsor GmbH

Withdrawn

JS001+IMP4297 in Patients With Advanced Cancer

Advanced Cancer
Shanghai Junshi Bioscience Co., Ltd.
Sponsor GmbH

Recruiting

A Phase I Clinical Study of Recombinant Humanized Anti-BTLA Monoclonal Antibody (JS004) Injection Combined With Toripalimab Injection in Patients With Advanced Solid Tumors

Liver Cancer, Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Cervical Cancer, MSI-H Colorectal Cancer

China
Shanghai Junshi Bioscience Co., Ltd.
Sponsor GmbH

Recruiting

Evaluate the Preliminary Efficacy, Safety, and PK of Subcutaneous JS005 in Chinese Adult Patients With Active Nr-axSpA

Non-radiographic Axial Spondyloarthritis

China
Shanghai Junshi Bioscience Co., Ltd.
Sponsor GmbH

Recruiting

Evaluate the Preliminary Efficacy, Safety, and PK of Subcutaneous JS005 in Chinese Adult Patients With Active AS

Active Ankylosing Spondylitis

China
Shanghai Junshi Bioscience Co., Ltd.
Sponsor GmbH

Active, not recruiting

A Pharmacokinetic Study of JS002 in Healthy Subjects

Health Volunteer

China
Peking University
Shanghai Junshi Bioscience Co., Ltd.

Completed

Study of JS001 in Patients With Advanced Neuroendocrine Tumors

Neuroendocrine Tumors

China
Shanghai Zhongshan Hospital
Shanghai Junshi Bioscience Co., Ltd.; OrigiMed

Completed

A Study of the Efficacy and Safety of Chemotherapy Combined With Toripalimab in Advanced Biliary Tract Cancer

Biliary Tract Cancer

China
Shanghai Vinnerna Biosciences Co., Ltd.
Sponsor GmbH

Recruiting

The Mass Balance Study of [14C]JT001

Healthy Subjects

China
Shanghai Vinnerna Biosciences Co., Ltd.
Sponsor GmbH

Completed

A Study in Subjects With Liver Function Injury and Subjects With Normal Liver Function

Subjects With Liver Function Injury | Normal Liver Function Subject

China
Shanghai Vinnerna Biosciences Co., Ltd.
Sponsor GmbH

Completed

A Study in Elderly Chinese Subjects With Underlying Diseases

Elderly Subjects With Underlying Diseases

China
Shanghai Vinnerna Biosciences Co., Ltd.
Sponsor GmbH

Completed

A Study in Subjects With Renal Impairment Compared to Subjects With Normal Renal Function

Healthy Subjects | Subjects With Renal Impairment

China
Shanghai JunTop Biosciences Co., LTD
Sponsor GmbH

Terminated

JT001 (VV116) for the Early Treatment of COVID-19

Mild to Moderate COVID-19

China, Hong Kong
Shanghai Vinnerna Biosciences Co., Ltd.
Sponsor GmbH

Terminated

Efficacy and Safety of JT001 (VV116) Compared With Favipiravir

Moderate to Severe COVID-19

China, Uzbekistan
Shanghai Vinnerna Biosciences Co., Ltd.
Sponsor GmbH

Completed

JT001 (VV116) for the Treatment of COVID-19

Mild to Moderate COVID-19

China
Ikaria Bioscience Pty Ltd
SHANGHAI RONA Therapeutics Co.,Ltd.

Not yet recruiting

the Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects in Adult Subjects With Elevated LDL-C

To Reduce the LDL-C Level in Hypercholesteremia Patients
TopAlliance Biosciences
Shanghai Junshi Bioscience Co., Ltd.; CTI Clinical Trial and Consulting Services

Recruiting

Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies

Metastatic Solid Tumor | Advanced Unresectable Solid Tumor

United States
Zhejiang Cancer Hospital
Shanghai Junshi Bioscience Co., Ltd.

Suspended

A Study of Toripalimab Combined With Concurrent Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma.

Esophageal Squamous Cell Carcinoma

China
Shanghai Ark Biopharmaceutical Co., Ltd.
Ark Biosciences Pty Ltd.

Completed

Viral Inhibition in Children for Treatment of RSV (VICTOR)

RESPIRATORY SYNCYTIAL VIRUS INFECTIONS

Australia, Hong Kong, Israel, Lebanon, Malaysia, Poland, Taiwan, Turkey
Shanghai Junshi Bioscience Co., Ltd.
CTI Clinical Trial and Consulting Services; TopAlliance Biosciences, Inc.

Withdrawn

A Clinical Study of TAB006 in Patients With Previously Treated, Advanced Malignancies

Malignancies | Previously Treated, Advanced
Ark Biosciences Inc.
Shanghai Ark Biopharmaceutical Co., Ltd.

Not yet recruiting

A Study to Evaluate the Safety, Tolerability and Efficacy of AK3280 Cream on Hypertrophic Scar

Hypertrophic Scar

China
Ark Biosciences Inc.
Shanghai Ark Biopharmaceutical Co., Ltd.

Completed

A Study of AK3280 in Chinese Healthy Volunteers

Healthy

China
Ark Biosciences Inc.
Shanghai Ark Biopharmaceutical Co., Ltd.

Not yet recruiting

A Study to Evaluate the Efficacy and Safety of AK3280 in Patients With Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis

China
Norroy Bioscience Co., LTD

Recruiting

A Phase 1/2 Study of 177Lu-NYM032 Injection in mCRPC

Metastatic Castration-resistant Prostate Cancer

China
SK Bioscience Co., Ltd.

Completed

Safety and Immunogenicity of a SARS-CoV-2 Vaccine (NBP2001) in Healthy Adults (COVID-19)

COVID-19 (Healthy Volunteers)

Korea, Republic of
SK Bioscience Co., Ltd.

Completed

Immunogenicity and Safety Study of NBP615 in Healthy Female

Cervical Cancer

Korea, Republic of
Guangdong Provincial People's Hospital
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

Neoadjuvant Immunotherapy in Rare Mutations Localized NSCLC

Non-Small Cell Lung Cancer | BRAF V600 Mutation | MET Amplification | MET Exon 14 Skipping Mutation | RET Driver Mutation | Erb-B2 Receptor Tyrosine Kinase Exon 20 Mutation

China
Eli Lilly and Company
Shanghai Junshi Bioscience Co., Ltd.

Completed

A Study of LY3832479 (LY-CoV016) in Healthy Participants 1

Healthy

United States
Sun Yat-sen University
Shanghai Junshi Bioscience Co., Ltd.

Unknown

JS001 Combined With Regorafenib in Patients With Advanced Colorectal Cancer

Colorectal Cancer

China
Norroy Bioscience Co., LTD

Recruiting

Pharmacokinetics, Biodistribution, Radiation Dose and Safety Study of 68Ga-NYM032 in Patients

Prostate Cancer

China
Norroy Bioscience Co., LTD

Recruiting

Pharmacokinetics, Biodistribution, Radiation Dose and Safety Study of 68Ga-NYM005 in Patients

Clear Cell Renal Cell Carcinoma Metastatic

China
SK Bioscience Co., Ltd.

Completed

Immunogenicity and Safety of NBP607-QIV Compared to Agrippal in Children Aged 6 to 35 Months

Influenza

Korea, Republic of
Peking University People's Hospital
Shanghai Junshi Bioscience Co., Ltd.

Not yet recruiting

Neoadjuvant Toripalimab for Non-squamous NSCLC With EGFR Mutation

EGFR Positive Non-small Cell Lung Cancer | Non Squamous Non Small Cell Lung Cancer
Sun Yat-sen University
Shanghai Weike Bioscience Co., Ltd.

Not yet recruiting

A Two-blinded, Multicentre, Phase II/III RCT of Concurrent Chemo-radiotherapy Combined or Not Combined With TNF as the Therapy for LA-NPC

Nasopharyngeal Carcinoma | TNF | Chemo-radiotherapy
Sun Yan
Shanghai Junshi Bioscience Co., Ltd.

Not yet recruiting

Toripalimab Plus TPF Chemotherapy and Radiotherapy for LA-HPSCC

Hypopharyngeal Neoplasm Malignant Primary

China
Sun Yat-sen University
Shanghai Junshi Bioscience Co., Ltd.

Active, not recruiting

PD-1 Blockade Combined With De-intensification Radical Chemoradiotherapy in Nasopharyngeal Carcinoma (DIAMOND)

Nasopharyngeal Carcinoma

China

Clinical Trials Sponsored by Mabwell (Shanghai) Bioscience Co., Ltd.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Georgia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations